Lung Cancer TALK: A Review of Data from the IASLC 2020 World Conference on Lung Cancer - Episode 1

WCLC Updates in KRAS and Rare EGFR-Mutated NSCLC

February 26, 2021
Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center

Sarah Goldberg, MD, MPH, Yale School of Medicine

Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center

Heather A. Wakelee, MD, Stanford University Medical Center

Experts in thoracic oncology review data presented at the IASLC 2020 World Conference on Lung Cancer (WCLC) and discuss safety and efficacy of targeted agents for patients with KRAS- or EGFR-mutated non–small cell lung cancer (NSCLC).

Data from the following clinical trials are discussed:

  • PS0 1.07 - CodeBreaK 100: Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutated Non–Small Cell Lung Cancer
  • OA04.03 - Mobocertinib in NSCLC With EGFR Exon 20 Insertions: Results From EXCLAIM and Pooled Platinum-Pretreated Patient Populations
  • OA04.04 - Amivantamab in Postplatinum EGFR Exon 20 Insertion Mutant Non–Small Cell Lung Cancer